KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. 151.

    Cook LB, Melamed A, Niederer H, Valganon M, Laydon D, Foroni L, Taylor GP, Matsuoka M, Bangham CR.

    The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma.

    Blood. 2014 Jun 19;123(25):3925-31. doi: 10.1182/blood-2014-02-553602. Epub 2014 Apr 15. PMID: 24735963; PMCID: PMC4064332.

  2. 152.

    Azuma Y, Kükenshöner T, Ma G, Yasunaga J, Imanishi M, Tanaka G, Nakase I, Maruno T, Kobayashi Y, Arndt KM, Matsuoka M, Futaki S.

    Controlling leucine-zipper partner recognition in cells through modification of a-g interactions.

    Chem Commun (Camb). 2014 Jun 18;50(48):6364-7. doi: 10.1039/c4cc00555d. PMID: 24803110.

  3. 153.

    Muftuoglu Y, Sohl CD, Mislak AC, Mitsuya H, Sarafianos SG, Anderson KS.

    Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) using pre-steady-state kinetics.

    Antiviral Res. 2014 Jun;106:1-4. doi: 10.1016/j.antiviral.2014.03.001. Epub 2014 Mar 12. PMID: 24632447; PMCID: PMC4020981.

  4. 154.

    Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

    IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.

    Eur J Haematol. 2014 Jun;92(6):471-7. doi: 10.1111/ejh.12271. Epub 2014 Mar 3. PMID: 24443894.

  5. 155.

    Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H.

    EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.

    J Invest Dermatol. 2014 Apr;134(4):1158-1161. doi: 10.1038/jid.2013.467. Epub 2013 Nov 11. PMID: 24384694.

  6. 156.

    Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y, Shinohara A, Inoue Y, Ueda R, Tanaka T, Kim SW, Yamashita T, Heike Y, Fukuda T.

    Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.

    Eur J Haematol. 2014 Feb;92(2):137-46. doi: 10.1111/ejh.12214. Epub 2013 Nov 9. PMID: 24127668.

  7. 157.

    Tanaka-Nakanishi A, Yasunaga J, Takai K, Matsuoka M.

    HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization.

    Cancer Res. 2014 Jan 1;74(1):188-200. doi: 10.1158/0008-5472.CAN-13-0436. Epub 2013 Oct 31. PMID: 24177179.

  8. 158.

    Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H.

    Delayed emergence of HIV-1 variants resistant to 4′-ethynyl-2-fluoro-2′-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.

    Antivir Ther. 2014;19(2):179-89. doi: 10.3851/IMP2697. Epub 2013 Oct 25. PMID: 24162098.

  9. 159.

    Zhao T, Coutts A, Xu L, Yu J, Ohshima K, Matsuoka M.

    HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBPα signaling.

    Retrovirology. 2013 Dec 21;10:159. doi: 10.1186/1742-4690-10-159. PMID: 24359396; PMCID: PMC3880043.

  10. 160.

    Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, Ishizaka Y, Ito M, Aihara K, An DS, Koyanagi Y.

    HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo.

    PLoS Pathog. 2013;9(12):e1003812. doi: 10.1371/journal.ppat.1003812. Epub 2013 Dec 5. PMID: 24339781; PMCID: PMC3855622.

  11. 161.

    Salcedo Gómez PM, Amano M, Yashchuk S, Mizuno A, Das D, Ghosh AK, Mitsuya H.

    GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.

    Antimicrob Agents Chemother. 2013 Dec;57(12):6110-21. doi: 10.1128/AAC.01420-13. Epub 2013 Sep 30. PMID: 24080647; PMCID: PMC3837900.

  12. 162.

    Kawano Y, Kikukawa Y, Fujiwara S, Wada N, Okuno Y, Mitsuya H, Hata H.

    Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.

    Int J Oncol. 2013 Dec;43(6):1809-16. doi: 10.3892/ijo.2013.2134. Epub 2013 Oct 10. PMID: 24126540; PMCID: PMC3834117.

  13. 163.

    Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S.

    Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.

    Free Radic Biol Med. 2013 Dec;65:778-788. doi: 10.1016/j.freeradbiomed.2013.08.161. Epub 2013 Aug 20. PMID: 23973637.

  14. 164.

    Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.

    Effects of substitutions at the 4′ and 2 positions on the bioactivity of 4′-ethynyl-2-fluoro-2′-deoxyadenosine.

    Antimicrob Agents Chemother. 2013 Dec;57(12):6254-64. doi: 10.1128/AAC.01703-13. Epub 2013 Oct 7. PMID: 24100493; PMCID: PMC3837839.

  15. 165.

    Miura M, Yasunaga J, Tanabe J, Sugata K, Zhao T, Ma G, Miyazato P, Ohshima K, Kaneko A, Watanabe A, Saito A, Akari H, Matsuoka M.

    Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection.

    Retrovirology. 2013 Oct 24;10:118. doi: 10.1186/1742-4690-10-118. PMID: 24156738; PMCID: PMC4016002.

  16. 166.

    Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H.

    P2′ benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.

    Antimicrob Agents Chemother. 2013 Oct;57(10):4920-7. doi: 10.1128/AAC.00868-13. Epub 2013 Jul 22. PMID: 23877703; PMCID: PMC3811474.

  17. 167.

    Ghosh AK, Parham GL, Martyr CD, Nyalapatla PR, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.

    Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.

    J Med Chem. 2013 Sep 12;56(17):6792-802. doi: 10.1021/jm400768f. Epub 2013 Aug 15. PMID: 23947685; PMCID: PMC3800042.

  18. 168.

    Ma G, Yasunaga J, Fan J, Yanagawa S, Matsuoka M.

    HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells.

    Oncogene. 2013 Sep 5;32(36):4222-30. doi: 10.1038/onc.2012.450. Epub 2012 Oct 8. PMID: 23045287.

  19. 169.

    Tokunaga K, Yamaguchi S, Iwanaga E, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

    High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.

    Eur J Haematol. 2013 Sep;91(3):201-8. doi: 10.1111/ejh.12155. Epub 2013 Jul 7. PMID: 23751147.

  20. 170.

    Hachiya A, Reeve AB, Marchand B, Michailidis E, Ong YT, Kirby KA, Leslie MD, Oka S, Kodama EN, Rohan LC, Mitsuya H, Parniak MA, Sarafianos SG.

    Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs.

    Antimicrob Agents Chemother. 2013 Sep;57(9):4554-4558. doi: 10.1128/AAC.00283-13. Epub 2013 Jun 24. PMID: 23796932; PMCID: PMC3754316.

  21. 171.

    Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, Kinashi T, Matsuoka M.

    HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression.

    PLoS Pathog. 2013 Sep;9(9):e1003630. doi: 10.1371/journal.ppat.1003630. Epub 2013 Sep 19. PMID: 24068936; PMCID: PMC3777874.

  22. 172.

    Mizuhara T, Kato T, Hirai A, Kurihara H, Shimada Y, Taniguchi M, Maeta H, Togami H, Shimura K, Matsuoka M, Okazaki S, Takeuchi T, Ohno H, Oishi S, Fujii N.

    Structure-activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents.

    Bioorg Med Chem Lett. 2013 Aug 15;23(16):4557-61. doi: 10.1016/j.bmcl.2013.06.026. Epub 2013 Jun 19. PMID: 23845222.

  23. 173.

    Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S; SPARE study team.

    Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.

    PLoS One. 2013 Aug 8;8(8):e73639. doi: 10.1371/journal.pone.0073639. PMID: 23951362; PMCID: PMC3738570.

  24. 174.

    Shimane K, Kawaji K, Miyamoto F, Oishi S, Watanabe K, Sakagami Y, Fujii N, Shimura K, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.

    HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

    Antimicrob Agents Chemother. 2013 Aug;57(8):4035-8. doi: 10.1128/AAC.00237-13. Epub 2013 May 20. PMID: 23689710; PMCID: PMC3719727.

  25. 175.

    Michailidis E, Ryan EM, Hachiya A, Kirby KA, Marchand B, Leslie MD, Huber AD, Ong YT, Jackson JC, Singh K, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

    Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.

    Retrovirology. 2013 Jun 24;10:65. doi: 10.1186/1742-4690-10-65. PMID: 23800377; PMCID: PMC3695782.

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.